Navigation Links
Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
Date:12/28/2007

PITTSBURGH, Dec. 28 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets (OTC), 5 mg and 10 mg.

Cetirizine HCl Tablets are the generic version of Pfizer's Zyrtec(R) Tablets, which had U.S. sales of approximately $1.4 billion for the 12 months ending Sept. 30, 2007.

This product will be shipped immediately.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Bill ... 2017 collaboration with the American Heart Association; “Howe” Healthy is Your Heart Drawing ... stay healthy and active. Each year, Bill Howe Plumbing, Heating & Air receives over ...
(Date:1/19/2017)... MD (PRWEB) , ... January 19, 2017 , ... Sales ... six new clients into the US market. , Over the past 20 years SFI ... past 4 weeks SFI has launched six new clients into the US market. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Breast Surgery Symposium, a conference where hundreds of surgeons from over fifteen different ... Covering topics from cosmetic breast augmentation to breast reconstruction for breast ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a new ... the benefits of fidgeting to relieve stress and anxiety. No one was more ... Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the popular ...
(Date:1/18/2017)... ... January 18, 2017 , ... Visually learn facts and ... OTC antiperspirant, Certain Dri. , Excessive sweating and hyperhidrosis are common conditions that ... infographic to explain the seven types of hyperhidrosis. This visual creates awareness about ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... , Jan. 18, 2017 The Global Therapy ... and access to partnering deals and agreements entered into ... in partnering deals - Top deals by value - ... development, technology type The report provides understanding and ... by the world,s leading healthcare companies. The report ...
(Date:1/19/2017)... South Korea Insulin Delivery Market Outlook ... Korea Insulin Delivery Market Outlook to 2022", provides key ... The report provides value, in millions of US dollars, ... segments - Insulin Pens, Insulin Pumps, Insulin Syringes and ... company shares and distribution shares data for each of ...
Breaking Medicine Technology: